(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 10.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.07%.
Veracyte's revenue in 2026 is $541,743,000.On average, 15 Wall Street analysts forecast VCYT's revenue for 2026 to be $46,922,066,068, with the lowest VCYT revenue forecast at $44,892,939,055, and the highest VCYT revenue forecast at $48,677,504,302. On average, 15 Wall Street analysts forecast VCYT's revenue for 2027 to be $52,718,203,946, with the lowest VCYT revenue forecast at $49,386,860,934, and the highest VCYT revenue forecast at $55,547,651,209.
In 2028, VCYT is forecast to generate $58,196,767,089 in revenue, with the lowest revenue forecast at $52,970,348,711 and the highest revenue forecast at $60,968,763,646.